Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.

Lachaine, Jean; Charron, Jean-Nicolas; Gregoire, Jean C; Hegele, Robert A; Leiter, Lawrence A

Lachaine, Jean; Charron, Jean-Nicolas; Gregoire, Jean C; Hegele, Robert A; Leiter, Lawrence A.

Afiliação

Lachaine J; University of Montreal, Montreal, QC, Canada.
Charron JN; PeriPharm Inc., Montreal, QC, Canada.
Gregoire JC; PeriPharm Inc., Montreal, QC, Canada.
Hegele RA; Institut de cardiologie de Montréal, Montreal, QC, Canada.
Leiter LA; Robarts Research Institute, London, ON, Canada.

Clinicoecon Outcomes Res ; 15: 295-308, 2023.

Article em En | MEDLINE | ID: mdl-37101608

Palavras-chave

IPE; cardiovascular diseases; cost per QALY; cost-effectiveness; icosapent ethyl

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Health_economic_evaluation / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google